Registration
|
08:15 - 08:45 |
Welcome note from MarketsandMarkets
Nikita Parab, Associate Director, Conferences, MarketsandMarkets
|
08:50 - 08:55 |
Opening Remarks from the Chairman
Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah
|
08:55 - 09:00 |
Development of a Kit-Based Assay for Assessing Homologous Recombination Deficiency (HRD) in Ovarian Cancer
Amy Wehn, Director, Companion Diagnostics, Merck
|
09:00 - 09:30 |
Challenges associated with Clinical Biomarker Validation |
End-to-end proteomics services for discovery, validation and deployment of novel biomarkers in drug development and clinical trials
Ian Pike, Chief Scientific Officer, Proteome Sciences PLC
|
09:30 - 10:00 |
Develop and Validate Cancer Methylation Panel Using Targeted Bisulfite NGS
Liying Yan, President, EpigenDx
|
10:00 - 10:25 |
Morning Refreshments and Poster Presentation | One-to-One Networking Meetings
|
10:30 - 11:15 |
Delivering CDx Excellence: Innovation and Partnerships
Deboleena Sarkar, Director Companion Diagnostics Business Development, Qiagen
|
11:15 - 11:45 |
BD Biosciences Advancing CDx and clinical trial assay development using flow cytometry
Scott Bornheimer , Associate Director, Medical & Scientific Affairs , BD Biosciences
|
11:45 - 12:15 |
Current and Future Liquid Biopsy Landscapes in Advanced Prostate cancer: Implications for Clinical Practice
Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah
|
12:15 - 12:45 |
Turning preclinical findings into clinic-ready biomarker assays to support the phase I/II of BT7480, a Bicycle tumor-targeted immune cell agonist®
Heather Cohen, Director, Translational Sciences, Bicycle Therapeutics
|
12:45 - 13:15 |
Lunch and Poster Presentation | One-to-One Networking Meetings
|
13:15 - 14:15 |
Role of Biomarkers in Personalized Medicine |
Precision Oncology Centric Development of Antibody Drug Conjugates
Rakesh Dixit, CEO, Bionavigen
|
14:15 - 14:45 |
T-cell engagers in immuno-oncology: challenges and advances in biomarker-driven clinical approaches
Majid Ghoddusi , Senior Director, Clinical Biomarkers, Poseida Therapeutics
|
14:45 - 15:15 |
Design of a comprehensive liquid biopsy assay to monitor real-time anti-tumor response in patients receiving an individualized neoantigen cancer vaccine
Desiree Schenk, Principal Scientist, Gritstone Oncology
|
15:15 - 15:45 |
Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings
|
15:45 - 16:30 |
Panel Discussion:
|
16:30 - 17:00 |
Innovation strategy for the most disruptive, turbulent, and transformative period in modern history. Thriving in the rapidly evolving field of precision medicine
George Pell, CEO and Founder, Thirty-Six
|
17:00 - 17:30 |
Closing Remarks from the Chairperson
Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah
|
17:30 - 17:55 |
Drinks Reception & Networking
|
17:35 - 17:35 |
End of Day 1
|
17:35 - 17:35 |